Cargando…
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
PURPOSE: Molecular profiling performed in the research setting usually does not benefit the patients that donate their tissues. Through a prospective protocol, we sought to determine the feasibility and utility of performing broad genomic testing in the research laboratory for discovery, and the uti...
Autores principales: | Arango, Natalia Paez, Brusco, Lauren, Shaw, Kenna R. Mills, Chen, Ken, Eterovic, Agda Karina, Holla, Vijaykumar, Johnson, Amber, Litzenburger, Beate, Khotskaya, Yekaterina B., Sanchez, Nora, Bailey, Ann, Zheng, Xiaofeng, Horombe, Chacha, Kopetz, Scott, Farhangfar, Carol J., Routbort, Mark, Broaddus, Russell, Bernstam, Elmer V., Mendelsohn, John, Mills, Gordon B., Meric-Bernstam, Funda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522029/ https://www.ncbi.nlm.nih.gov/pubmed/28415679 http://dx.doi.org/10.18632/oncotarget.16018 |
Ejemplares similares
-
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2019) -
Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers
por: Kopetz, Scott, et al.
Publicado: (2019) -
ALK: a tyrosine kinase target for cancer therapy
por: Holla, Vijaykumar R., et al.
Publicado: (2017) -
Clinical next generation sequencing to identify actionable aberrations in a phase I program
por: Boland, Genevieve M., et al.
Publicado: (2015) -
ClinSeK: a targeted variant characterization framework for clinical sequencing
por: Zhou, Wanding, et al.
Publicado: (2015)